Head to head
Ginkgo Bioworks vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: DNA · VRTX
DNA
Ginkgo Bioworks
11.02-3.92%
1-year price shape — -23% over the period
Quant Rating D · 44/100
vs
VRTX
Vertex Pharmaceuticals
503.51-0.42%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| DNA | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 11.02 | 503.51 |
| Change today | -3.92% | -0.42% |
| 1-year return | -22.6% | +23.2% |
| Market cap | $742.09M | $127.62B |
| 52-week range | 5.37 – 18.22 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -2.20 | 29.32 |
| P/E percentile, own 5-yr range | 30th | 74th |
| P/B | 1.77 | 6.30 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -5.64 | 15.32 |
| Net profit (TTM) | $-379.80M | $3.88B |
| Revenue (TTM) | $111.86M | $12.59B |
| Revenue growth (YoY) | -48.5% | +12.5% |
| Gross margin | 68.0% | 86.0% |
| Operating margin | -228.6% | 37.9% |
| Net margin | -219.6% | 35.0% |
| Free cash flow (TTM) | $-174.80M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 59.1% | 97.2% |
| Insider activity (12mo) | 18 buy / 32 sell | 25 buy / 25 sell |
| Short interest (% of float) | 10.6% | 1.9% |
| Analyst consensus | 33% hold / 67% sell (3) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $7 (-36%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (44) | C (67) |
| Company | ||
| Employees | 485 | 6,400 |
| Founded | 2008 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.